Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer.
Twenty-six cycles of high-dose ifosfamide + mesna (HD-IFO + M) were applied to seven female patients with advanced breast cancer refractory to prior treatment, using three different durations of continuous infusion (4, 24, and 48 h) every 3 weeks. To evaluate the most tolerable time schedule, the duration of the infusions was changed periodically in each patient. Toxicity was low in general, but continuous infusion of HD-IFO + M over 24 h appeared to be the best tolerated. One partial response lasting 27 weeks was achieved and four patients achieved stable disease lasting from 9 to 12 weeks.
Steger
G G
GG
Department of Chemotherapy, University of Vienna, Austria.
Dittrich
C
C
Schlappack
O
O
Mader
R
R
Herold
C
C
Brade
W P
WP
Keller
A
A
Moser
K
K
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects*; D008623:Mercaptoethanol / Q000031:analogs & derivatives*; D015080:Mesna / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged
D008623:Mercaptoethanol; D015080:Mesna; D007069:Ifosfamide